Arch Biopartners Inc

TSXV:ARCHCanadaView on OTCQB

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

Contact Information

Headquarters

545 King St W.TORONTO, ON, Canada M5X 1A1

Phone

647-428-7031

Fax

647-351-3565

Executives

President, Chief Executive Officer, Director

Richard Muruve

Chief Financial Officer, Director

Andrew Bishop

Chief Science Officer

Daniel Muruve

Independent Director

Claude Allary

Independent Director

Richard Rossman